Kyverna Therapeutics Inc (KYTX)

Nov 05, 2025

Why Kyverna Therapeutics Inc. stock remains undervalued2025 Institutional Moves & Weekly Breakout Stock Alerts - newser.com

Nov 05, 2025

Nov 05, 2025

How sentiment analysis helps forecast Kyverna Therapeutics Inc.2025 Key Lessons & Safe Entry Trade Signal Reports - newser.com

Nov 05, 2025

Nov 05, 2025

Will Kyverna Therapeutics Inc. stock keep outperforming rivalsJuly 2025 Rallies & Risk Controlled Swing Alerts - fcp.pa.gov.br

Nov 05, 2025

Nov 05, 2025

How Kyverna Therapeutics Inc. stock reacts to bond yieldsEarnings Overview Summary & Pattern Based Trade Signal System - fcp.pa.gov.br

Nov 05, 2025

Nov 05, 2025

Is Kyverna Therapeutics Inc. stock a buy before product launchesShare Buyback & Free Verified High Yield Trade Plans - newser.com

Nov 05, 2025

Nov 05, 2025

What the charts say about Kyverna Therapeutics Inc. todayPortfolio Update Summary & Reliable Intraday Trade Plans - newser.com

Nov 05, 2025

Nov 05, 2025

Pattern recognition hints at Kyverna Therapeutics Inc. upsideWeekly Market Report & Fast Moving Stock Watchlists - newser.com

Nov 05, 2025

Nov 05, 2025

Using economic indicators to assess Kyverna Therapeutics Inc. potentialJuly 2025 Rallies & Free Safe Entry Trade Signal Reports - newser.com

Nov 05, 2025

Nov 05, 2025

Can machine learning forecast Kyverna Therapeutics Inc. recoveryQuarterly Portfolio Report & Consistent Profit Trading Strategies - newser.com

Nov 05, 2025

Nov 04, 2025

Kyverna secures $150 million loan facility to advance autoimmune therapies By Investing.com - Investing.com Australia

Nov 04, 2025

Nov 04, 2025

Is Kyverna Therapeutics Inc. stock attractive for passive investorsEarnings Trend Report & Daily Growth Stock Tips - newser.com

Nov 04, 2025

Nov 04, 2025

Is Kyverna Therapeutics Inc. stock vulnerable to regulatory risks2025 Growth vs Value & Real-Time Volume Triggers - newser.com

Nov 04, 2025

Nov 03, 2025

Kyverna secures $150 million loan facility to advance autoimmune therapies - Investing.com

Nov 03, 2025

Nov 03, 2025

Kyverna Therapeutics Secures $150 Million Loan Facility - TipRanks

Nov 03, 2025

Nov 03, 2025

Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance - The Manila Times

Nov 03, 2025

Nov 03, 2025

[8-K] Kyverna Therapeutics, Inc. Reports Material Event | KYTX SEC FilingForm 8-K - Stock Titan

Nov 03, 2025

Nov 03, 2025

Kyverna (Nasdaq: KYTX) secures up to $150M non-dilutive financing maturing 2030 - Stock Titan

Nov 03, 2025

Nov 03, 2025

Kyverna Therapeutics Reports Positive Phase 2 Trial Results - MSN

Nov 03, 2025

Nov 03, 2025

Will Kyverna Therapeutics Inc. stock deliver long term returnsMarket Growth Review & Weekly Market Pulse Alerts - newser.com

Nov 03, 2025

Nov 03, 2025

Combining price and volume data for Kyverna Therapeutics Inc.Weekly Trade Summary & Safe Entry Momentum Tips - newser.com

Nov 03, 2025

Oct 31, 2025

Analysts Conflicted on These Healthcare Names: Kyverna Therapeutics, Inc. (KYTX), Disc Medicine (IRON) and Baxter International (BAX) - The Globe and Mail

Oct 31, 2025

Oct 31, 2025

Kyverna Therapeutics (KYTX) Price Target Increased by 16.46% to 23.46 - MSN

Oct 31, 2025

Oct 30, 2025

Kyverna Therapeutics, Inc. (KYTX) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK

Oct 30, 2025

Oct 30, 2025

Promising Phase 2 Data and Favorable Safety Profile Drive Buy Rating for Kyverna Therapeutics’ KYV-101 - TipRanks

Oct 30, 2025

Oct 30, 2025

What is HC Wainwright's Estimate for KYTX Q3 Earnings? - MarketBeat

Oct 30, 2025

Oct 30, 2025

Kyverna Therapeutics Advances in Lupus Nephritis Treatment with KYV-101 CAR T-Cell Therapy - MSN

Oct 30, 2025

Oct 30, 2025

Kyverna’s CAR T Therapy Sets 'New Efficacy Standard' in Myasthenia Gravis, De-Risking Phase III Trials - BioSpace

Oct 30, 2025